Pluri Inc. Common Stock

PLURNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
1.01 USD
↘ 0.02 (1.94%)AT CLOSE (03:59 PM EDT)
1.02
↗ 0.01 (0.99%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
1.02
↗ 0.01 (0.99%)
🔴Market: CLOSED

Shares of Pluri Inc. Common Stock (PLUR) are trading at $1.01. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (113.5%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Oct 2, 2026.

Open?$1.04
High?$1.06
Low?$1.01
Prev. Close?$1.03
Volume?10.6K
Avg. Volume?24.8K
VWAP?$1.05
Rel. Volume?0.43x
Bid / Ask
Bid?$0.83 × 100
Ask?$1.26 × 100
Spread?$0.43
Midpoint?$1.05
Valuation & Ratios
Market Cap?12.5M
Shares Out?12.3M
Float?6.1M
Float %?56.1%
P/E Ratio?N/A
P/B Ratio?-0.59
EPS?-$1.93
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsFood & Agriculture›Alternative Proteins & Plant-Based
Employees
113
Market Cap
12.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.pluri-biotech.com
Listed
1991-10-09
Address
MATAM ADVANCED TECHNOLOGY PARK
HAIFA,
Phone: 972-74-710-7171
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
17
Short Sent.?
80
Piotroski F-Score?2/9Weak
Altman Z-Score?-30.45Distress
Confidence?46%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.33%Low
Short Interest?19.9K
Days to Cover?1.4
Free Float6.1M
Avg Daily Volume14.3K
Settlement Date2026-09-15
Financial Health
Current Ratio?0.27Weak
Quick Ratio?0.27Weak
Cash Ratio?0.11Low
Debt/Equity?-1.31Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-0.59CHEAP▾
P/S?
Peers
100
S&P
3
12.27HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
35.80HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
113.5%STRONG▾
ROA?
S&P
3
-95.8%WEAK▾
Cash Flow & Enterprise
FCF?$-20221000
Enterprise Value?$36.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist